FDA Grants SeaStar Medical Two New Breakthrough Device Designations for SCD Therapy to Treat Systemic Inflammatory Response in Adult and Pediatric Patients Undergoing Cardiac Surgery
In a significant advancement for pediatric care, SeaStar Medical has secured two new Breakthrough Device Designations from the U.S. Food and Drug Administration (FDA) for its Selective Cytopheretic Device (SCD) therapy. These designations target the […]
